AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena. Top-line results from the CLL14 ...

Venclexta, co-developed by AbbVie and Roche's Genentech unit, has been approved in second line for patients who have a 17p deletion detected in an approved test.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years ...

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Lifestyle Expert Jennifer Bonner discusses chronic lymphocytic leukemia, or CLL, and the exciting advancements in its ...

In response, pharmaceutical companies filed a host of lawsuits, claiming HRSA lacks the authority to compel delivery of ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The company boasts a lineup of medicines such as Skyrizi and Rinvoq in immunology, Venclexta and Imbruvica in oncology, Vraylar and Qulipta in neuroscience, and more. AbbVie can no longer rely on ...

Examples of targeted therapy include Calquence (acalabrutinib), Imbruvica (ibrutinib), and Venclexta (venetoclax). Monoclonal antibodies target specific proteins on cancer cells, marking them for ...

Examples of these medications are Bruton tyrosine kinase (BTK) inhibitors like Calquence (acalabrutinib) and Imbruvica (ibrutinib), and antiapoptotic protein B cell lymphoma 2 (BCL2) inhibitors like ...